Infusion Facility Parameters
Active Inspection
Section 503A/503B FDA statutory distinction for sterile injectable drugs
Each additive adds potential pyrogen and microbial load without strict laminar hood sterile prep
Batch Sterility & Endotoxin Testing Verified
Certificate of Analysis (CoA) from certified third-party lab
0.22-Micron In-line Bacterial Filter Used
Removes particulates and bacterial contaminants prior to vein entry
High volume without cleanroom automation multiplies outbreak vectors
Clinical Safety Assessment
Live Evaluation
| Regulatory Status | Violation of FDA Section 503A/503B compounding standards |
|---|---|
| FDA / CDC Warning Triggered | YES - High Alert Active |
| Bacterial Contamination Probability | High (Unsterile bulk powder compounding) |
| Endotoxin / Pyrogen Risk | Severe - Unscreened non-pyrogen-free raw minerals |
| Compounding Facility Type | Non-cGMP In-House Powder Manipulation |
Mandatory Safety Action
Immediate suspension of infusion services and recall of unverified vials
Audit Documentation & Clinical Records